logo

English
  • Svenska
  • About Us
    About Us
      • This is Calliditas
      • Vision and Strategy
      • Board of Directors
      • Management Team
      • Our History
      • Corporate Responsibility
        • Expanded Access Policy
      • Careers
  • Science
    Science
      • Our Pipeline
      • Nefecon (ex-US Markets)
      • Setanaxib – NOX Platform
      • Orphan drugs
  • Our Product
  • Governance
    Governance
      • Corporate Governance
      • Corporate Governance Reports
      • Corporate Structure
      • General Meeting
        • Annual general meeting 2022
        • General meetings
      • Nomination Committee
        • Nomination committees
      • Board and Committees
        • Board of Directors
        • Board fees
        • Work of the Board of Directors
        • Committees
      • Management
        • Management team
      • Remuneration
      • Internal Control and Risk Management
      • Auditor
      • Articles of Association
  • Investors
    Investors
      • The Share
        • Trading information
        • Ownership structure
        • Share capital development
        • Dividend policy
        • Analyst coverage
      • Financial Reports and Presentations
      • SEC Filings
      • Press Releases
      • Financial Calendar
      • IR Calendar
      • Subscribe
      • Contacts
      • Investor FAQs
  • Media
    Media
      • Press releases
      • Calliditas in Media
      • Calliditas Media Kit
      • TARPEYO Media Kit (US audience only)
      • Subscribe
      • Contacts
  • Contact Us
    Contact Us
      • Offices
      • Partnerships and Inquires
      • Investor Relations
      • Media
      • Medical Inquiries
  • Svenska

Press Releases

Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Regulatory press releases
  • Non-regulatory press releases
  • All press releases
2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2012
  • 2010
  • 2009
  • 2008
  • All years
May 19, 2022

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

May 19, 2022

Calliditas receives positive CHMP opinion in IgA nephropathy

May 18, 2022

Interim Report Q1, 2022

Apr 29, 2022

Number of shares and votes in Calliditas Therapeutics

Apr 27, 2022

Calliditas Therapeutics’ 2021 Annual Report Published

Apr 14, 2022

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Feb 24, 2022

Year-End Report, 2021

  • Media
    • Press Releases
    • Calliditas in Media
    • Subscribe
    • Contacts

Calliditas Therapeutics AB
D5, Kungsbron 1
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

  • Privacy policy
  • About cookies

© Calliditas Therapeutics AB 2022